Director and CEO
Thomas is a co-founder, the Chief Executive Officer and a Board member of Oxular Limited. He is an experienced and successful entrepreneur who has helped to build four previous private equity-backed ventures. He was formerly co-founder and Chief Executive Officer of Aciex Therapeutics, where he brought its lead program to NDA and led the company through a successful M&A exit.
Director and CSO
Dr. Rafiq Hasan
Dina is a partner with NeoMed. She has been investing in the private equity and venture capital healthcare industry in Europe and the US since 2001. She was previously at 3i plc in London and Index Ventures in Geneva and has worked in the private equity and venture capital healthcare industry in Europe and the US since 2001. Dina is a Board member of Oxular Limited and TopiVert Ltd. She is a CFA charterholder and holds a Ph.D. degree in Molecular and Cellular Biology from Paris VI University, France and carried out postdoctoral research at Brown University, Providence, US, and at the Fox Chase Cancer Centre, Philadelphia, US.
Christina is co-founder and Managing Director of V-Bio Ventures. Christina has more than 15 years of investment experience in European Venture Capital. She was previously a partner with Forbion Capital Partners (formerly ABN AMRO Capital) where she led and managed a series of successful biotech investments since 2001. Christina has a scientific background, holding a PhD in Developmental Biology from the University of Cologne, Germany, and an MSc in Biology from the University of Darmstadt, Germany.
Tassos is an Investment Manager at IP Group. He specialises in early stage investing in the life science sector. Before joining IP Group, Tassos was a business development executive at CRUK Commercial Partnerships (ex CRT) where he led the intellectual property sourcing, licensing and spin-out creation of CRUK-funded technologies. He has experience in technology transfer both in the states and the UK and has also held an investment analyst role with SR One, GSK’s venture capital arm. Tassos did a PhD in molecular oncology at the University of Oxford and a postdoc at the University of Chicago.